EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Emerging roles of PARP-1 driven dual inhibitors in cancer therapy: SAR-guided strategies and synthetic lethality

Ryena Dhir, Pitam Ghosh, Dinki Sharma, Vivek Asati

Future Medicinal Chemistry · 2026

DOI: 10.1080/17568919.2026.2619466 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Medicinal Chemistry, 2026. Verfasst von Ryena Dhir und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Neoplasms, Poly (ADP-Ribose) Polymerase-1, Antineoplastic Agents. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly (ADP-ribose) polymerase-1 (PARP-1) plays an important role in DNA damage repair and preservation of genomic integrity, making it promising target in oncology. PARP-1 inhibitors (PARP-1i) employ synthetic lethality to specifically target cells with deficiency in homologous recombination repair, such as those with BRCA1/2 mutation and other DNA impairments. Although PARP-1 inhibitors have shown clinical success, challenges like acquired resistance and limited efficacy are still matters of concern. Increasing evidence supports the potential of dual-targeting inhibitors that target PARP-1 along with other oncogenic drivers (e.g. HDAC, EGFR, and CDK) to amplify anti-proliferative activity and surmount resistance mechanism. This review comprehensively provides in-depth investigation of dual inhibitors in context to PARP-1, evaluating their design rationale, structure activity relationship (SARs), pharmacological properties, synthetic scheme, and more. By combining mechanistic insights with drug discovery, this work aims to create a road map for generating next-generation PARP-1 inhibitors, providing strategic recommendations in order to improve therapeutic efficacy and broaden clinical applicability across diverse cancer types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsNeoplasmsPoly (ADP-Ribose) Polymerase-1Antineoplastic AgentsHumansStructure-Activity RelationshipSynthetic Lethal MutationsAnimals

Stichwörter der Autor:innen

BRCA mutationCDK9EGFRHDACHRRPARP-1

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsPoly (ADP-Ribose) Polymerase-1Antineoplastic AgentsPARP1 protein, human

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India.

Zitieren

APA

Dhir, R., Ghosh, P., Sharma, D., & Asati, V. (2026). Emerging roles of PARP-1 driven dual inhibitors in cancer therapy: SAR-guided strategies and synthetic lethality. Future Medicinal Chemistry. https://doi.org/10.1080/17568919.2026.2619466

Vancouver

Dhir R, Ghosh P, Sharma D, Asati V. Emerging roles of PARP-1 driven dual inhibitors in cancer therapy: SAR-guided strategies and synthetic lethality. Future Medicinal Chemistry. 2026. doi:10.1080/17568919.2026.2619466

BibTeX
@article{Dhir2026,
  author = {Dhir, Ryena and Ghosh, Pitam and Sharma, Dinki and Asati, Vivek},
  title = {Emerging roles of PARP-1 driven dual inhibitors in cancer therapy: SAR-guided strategies and synthetic lethality},
  journal = {Future Medicinal Chemistry},
  year = {2026},
  doi = {10.1080/17568919.2026.2619466}
}
Kostenlos starten →